In the Phase III VAYHIT2 trial, ianalumab combined with eltrombopag significantly prolonged time to treatment failure and ...

Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 ...

The pharma company said the drug combined with eltrombopag demonstrated a significant improvement in time to treatment ...

Ianalumab added to eltrombopag significantly prolonged the time to treatment failure (TTF) in adults with primary immune thrombocytopenia (ITP), a B cell-driven autoimmune disease, according to phase ...

Ianalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids1,2 Patients treated ...

Novartis (NYSE:NVS) announced that its investigational antibody, ianalumab, combined with eltrombopag, successfully met the ...

Novartis (NYSE:NVS) (SIX:NOVN) said its experimental antibody ianalumab, used in combination with eltrombopag, achieved the ...

A day after posting a pair of phase 3 wins for the tricky indication of Sjögren's syndrome, the Swiss pharma has unveiled a ...

However, eltrombopag and romiplostim should never be considered as front-line treatment of the disease, George said. “These drugs are very expensive and they are maintenance therapies,” he said.

Eltrombopag (Promacta) generic is a thrombopoietin (TPO) receptor agonist, prescribed for immune (idiopathic) thrombocytopenic purpura (ITP). It helps the bone marrow to produce more platelets.

Adults with chronic or persistent immune thrombocytopenia maintained ideal platelet counts and decreased bleeding rate after treatment with eltrombopag, according to long-term efficacy data from ...

Eltrombopag is an oral thrombopoietin-receptor agonist approved for use in patients with chronic immune thrombocytopenia. A phase 2 study showed that eltrombopag could increase platelet counts in ...